Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth
Novartis (NVS) has upgraded its full-year 2026 core operating income guidance to in-line or low-single-digit growth, reversing previous projections of a decline. This positive shift follows a third quarter characterized by 4% net sales growth and a significant 7% reduction in selling, general, and administrative (SG&A) expenses. The company's ability to offset revenue losses from patent expirations with high-performing new launches is central to its long-term strategy. Specifically, management increased peak sales projections for Rhapsido to over $4 billion across combined indications. Novartis aims to leverage these efficiencies and pipeline successes to reach a 40% core operating margin target by 2029.
Coverage
- NHI outlines $4.68-$4.70 2026 NFFO guidance while targeting high single-digit to low double-digit organic SHOP NOI growth
- American Healthcare REIT Raises 2026 Guidance Following Consistent Same-Store NOI Growth
- Agilysys Raises Full-Year Guidance Following Record Sales and Subscription Growth
- Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth
- STRYKER CORP - 8-K Filing
- WASTE MANAGEMENT INC - 8-K Filing
- Novartis Reports Q3 2026 Growth Driven by Priority Brands Amid Generic Competition